by clicking the arrows at the side of the page, or by using the toolbar.
by clicking anywhere on the page.
by dragging the page around when zoomed in.
by clicking anywhere on the page when zoomed in.
web sites or send emails by clicking on hyperlinks.
Email this page to a friend
Search this issue
Index - jump to page or section
Archive - view past issues
Australian Journal of Pharmacy : May 2008
• SMS reminders encouraging quitters to return for their second CHAMPIX prescription; and • quitters can customise their level of interaction with the program. Remember to ask your CHAMPIX customers whether they have enrolled in the program. Pfizer will support you in this category by offering a case study-based education program for pharmacists and GPs: Clearing the Smoke—current and future treatment options in smoking cessation. This education program will assist in building the smoking cessation category in your pharmacy by helping you identify your customers readiness to quit and tailoring treatments to their needs. Pharmacists can participate in the Clearing the Smoke program through an interactive two-hour evening workshop or through online learning modules, both of which will attract PSA CPD points. The online learning modules will be available in late May 2008 and can be found at www.clearingthesmoke.com.au. For the pharmacy assistant, Pfizer has also developed a smoking cessation educational tool (unbranded) to train pharmacy assistants in the mechanisms underlying nicotine addiction and explain the treatment options available to customers who want to stop smoking. Your Pfizer representative will be calling on you soon with further information about ‘The Master’ campaign and can provide details relating to ‘My Time to Quit’, the Clearing the Smoke CPD activities and pharmacy assistant training. Breaking the hold of nicotine addiction The powerful and manipulative hold of nicotine addiction means quitting is often an ongoing process, with most smokers making five to seven attempts before they finally succeed.5 CHAMPIX has a unique dual action, binding to the same Champix: 12 Weeks treatment SCript one CoMbINATIoN PACk (Four weeks supply) • Clearly labelled packs are designed for ease of use • When the patient starts taking Champix they should be advised to continue smoking for at least one week, then quit during week 24 receptor as nicotine to deliver the power to help break its hold4,5 * • Partial agonist effect— reduces cravings and withdrawal symptoms as nicotine levels decline5,7,8 • Antagonist effect—reduces feelings of reward and satisfaction associated with smoking, and may prevent a full relapse if a cigarette is smoked5,7,8 Quitting power Worldwide, over 4 million quitters have been prescribed CHAMPIX.9 In a head-to-head clinical trial, CHAMPIX was shown to help more patients quit smoking compared to those using nicotine replacement therapy (NRT) patches at 12 • Mild to moderate nausea may occur early in treatment, but usually decreases over time.6,7 o Taking CHAMPIX after food and/or with a full glass of water may help reduce nausea12 • Remind patient to make a GP appointment for second script weeks.10‡ At the end of the 12 week treatment period the odds of quitting were around two times greater with CHAMPIX than with NRT patches.10 Patients taking CHAMPIX reported significantly greater reductions in cravings, withdrawal symptoms† and smoking satisfaction compared to those on NRT patches.10 Similar results were seen when CHAMPIX was compared to bupropion, with patients two times more likely to quit after 12 weeks of CHAMPIX treatment, and also more likely to be smoke-free at 12 months.7,8,11,§ ®Registered trademark Pfizer Australia Pty Limited, ABN 50 008 422 348, 38-42 Wharf Road, West Ryde NSW 2114. www.pfizer.com.au. Medical Information 1800 675 229. URSA PFA0242. Before prescribing, please review full Product Information available from Pfizer Australia Pty Ltd. Minimum Product information can be found in the primary advertisement in this publication. PBS information. this product is authority listed on the PBS as an aid for smoking cessation in adults. refer to PBS schedule for full information. *In vivo data. Animal or laboratory data do not necessarily predict clinical effects. † Defined as urge to smoke, negative effect, restlessness. ‡ In a direct, head-to-head, open-label, randomized, controlled trial CHAMPIX was shown to be more effective than NRT patches at the end of the 12-week CHAMPIX treatment period (NRT was used for 10 weeks). §One study Gonzales et al did not reach statistical significance at 52 weeks vs bupropion References: 1. Guide to quitting smoking. Available at http://www.cancer.org/docroot/PED/content/PED_10_13X_Guide_for_Quitting_Smoking.asp accessed March 2008. 2. Dani JA, Harris RA. Nature Neurosci, 2005; 8(11): 1465–70. 3. Jarvis MJ. Br Med J, 2004; 328:277–9. 4. CHAMPIX Approved Product Information. 5. Coe JW. J Med Chem, 2005; 48: 3474–7. 6. Hughes JR. CA Cancer J Clin, 2000; 50(3): 143–51. 7. Gonzales D, et al. JAMA, 2006; 296: 47–55. 8. Jorenby DE, et al. JAMA, 2006; 296: 56–63. 9. IMS Data to Q3 2007 10. Aubin H-J, et al. Thorax, 2008; In press. 11. Gonzales D, et al. Presented at 12th SRNT. Feb 15–18, 2006; Orlando, Florida. Abstract PA9-2. 12. CHAMPIX Consumer Medicine Information. The AusTrAliAn journAl of PhArmAcy vol.89 mAy 2008 17 SCript tWo MAINTENANCE PACkS (Eight weeks supply) The second script requires two maintenance packs to be dispensed (112 tablets made up of 2 x 56 tablet packs) • Encourage enrolment in www.mytimetoquit.com.au Find out about ways you can help your customers break the hold of nicotine addiction cover advertorial